Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 8
2003 6
2004 9
2005 7
2006 7
2007 8
2008 6
2009 8
2010 7
2011 4
2012 7
2013 6
2014 7
2015 3
2016 6
2017 3
2018 5
2019 7
2020 5
2021 4
2022 6
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Mitochondrial and cytosolic one-carbon metabolism is a targetable metabolic vulnerability in cisplatin-resistant ovarian cancer.
Wallace-Povirk A, O'Connor C, Dekhne AS, Bao X, Nayeen MJ, Schneider M, Katinas JM, Wong-Roushar J, Kim S, Polin L, Li J, Back JB, Dann CE, Gangjee A, Hou Z, Matherly LH. Wallace-Povirk A, et al. Among authors: matherly lh. Mol Cancer Ther. 2024 Feb 20. doi: 10.1158/1535-7163.MCT-23-0550. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38377173
Structural Characterization of 5-Substituted Pyrrolo[3,2-d]pyrimidine Antifolate Inhibitors in Complex with Human Serine Hydroxymethyl Transferase 2.
Katinas JM, Nayeen MJ, Schneider M, Shah K, Fifer AN, Klapper LM, Sharma A, Thalluri K, Van Nieuwenhze MS, Hou Z, Gangjee A, Matherly LH, Dann CE 3rd. Katinas JM, et al. Among authors: matherly lh. Biochemistry. 2024 Feb 7. doi: 10.1021/acs.biochem.3c00613. Online ahead of print. Biochemistry. 2024. PMID: 38324671
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.
Hurrish KH, Su Y, Patel S, Ramage CL, Zhao J, Temby BR, Carter JL, Edwards H, Buck SA, Wiley SE, Hüttemann M, Polin L, Kushner J, Dzinic SH, White K, Bao X, Li J, Yang J, Boerner J, Hou Z, Al-Atrash G, Konoplev SN, Busquets J, Tiziani S, Matherly LH, Taub JW, Konopleva M, Ge Y, Baran N. Hurrish KH, et al. Among authors: matherly lh. Biochem Pharmacol. 2024 Feb;220:115981. doi: 10.1016/j.bcp.2023.115981. Epub 2023 Dec 10. Biochem Pharmacol. 2024. PMID: 38081370
Multitargeted 6-Substituted Thieno[2,3-d]pyrimidines as Folate Receptor-Selective Anticancer Agents that Inhibit Cytosolic and Mitochondrial One-Carbon Metabolism.
Tong N, Wong-Roushar J, Wallace-Povirk A, Shah Y, Nyman MC, Katinas JM, Schneider M, O'Connor C, Bao X, Kim S, Li J, Hou Z, Matherly LH, Dann CE 3rd, Gangjee A. Tong N, et al. Among authors: matherly lh. ACS Pharmacol Transl Sci. 2023 Apr 26;6(5):748-770. doi: 10.1021/acsptsci.3c00020. eCollection 2023 May 12. ACS Pharmacol Transl Sci. 2023. PMID: 37200803 Free PMC article.
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis.
Hurrish KH, Su Y, Patel S, Ramage CL, Carter JL, Edwards H, Buck SA, Wiley SE, Hüttemann M, Polin L, Kushner J, Dzinic SH, White K, Bao X, Li J, Yang J, Boerner J, Hou Z, Al-Atrash G, Konoplev SN, Busquets J, Tiziani S, Matherly LH, Taub JW, Konopleva M, Ge Y, Baran N. Hurrish KH, et al. Among authors: matherly lh. Res Sq [Preprint]. 2023 Apr 28:rs.3.rs-2843025. doi: 10.21203/rs.3.rs-2843025/v1. Res Sq. 2023. PMID: 37162954 Free PMC article. Updated. Preprint.
Correction: Novel Pyrrolo[3,2-d]Pyrimidine Compounds Target Mitochondrial and Cytosolic One-Carbon Metabolism with Broad-spectrum Antitumor Efficacy.
Dekhne AS, Shah K, Ducker GS, Katinas JM, Wong-Roushar J, Nayeen MJ, Doshi A, Ning C, Bao X, Frühauf J, Liu J, Wallace-Povirk A, O'Connor C, Dzinic SH, White K, Kushner J, Kim S, Hüttemann M, Polin L, Rabinowitz JD, Li J, Hou Z, Dann CE, Gangjee A, Matherly LH. Dekhne AS, et al. Among authors: matherly lh. Mol Cancer Ther. 2023 Feb 1;22(2):287. doi: 10.1158/1535-7163.MCT-22-0766. Mol Cancer Ther. 2023. PMID: 36602953 No abstract available.
122 results